Wall Street Zen Upgrades HeartSciences (NASDAQ:HSCS) to “Hold”

HeartSciences (NASDAQ:HSCS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

HSCS has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of HeartSciences in a research note on Saturday, September 27th. Ascendiant Capital Markets dropped their price target on shares of HeartSciences from $15.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.50.

HeartSciences Trading Up 0.3%

NASDAQ:HSCS opened at $3.70 on Friday. The stock has a 50 day moving average of $3.48 and a 200-day moving average of $3.53. HeartSciences has a 52 week low of $2.52 and a 52 week high of $6.47. The firm has a market capitalization of $9.81 million, a PE ratio of -0.45 and a beta of 2.57.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Thursday, September 11th. The company reported ($1.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.41) by $0.83. As a group, analysts predict that HeartSciences will post -10.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HeartSciences stock. Astoria Strategic Wealth Inc. purchased a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,927 shares of the company’s stock, valued at approximately $53,000. Astoria Strategic Wealth Inc. owned about 1.75% of HeartSciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.24% of the company’s stock.

HeartSciences Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.